Column Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Column Capital Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$98.5K	Hold	1,422	–	–	0.01%	220
2023 Q2	$134K	Hold	1,422	–	–	0.02%	184
2023 Q1	$118K	Hold	1,422	–	–	0.02%	198
2022 Q4	$106K	Sell	1,422 -999	-41%	-$77K	0.02%	197
2022 Q3	$200K	Hold	2,421	–	–	0.04%	119
2022 Q2	$230K	Hold	2,421	–	–	0.04%	102
2022 Q1	$285K	Buy	2,421 +200	+9%	+$22.4K	0.05%	102
2021 Q4	$288K	Sell	2,221 -77	-3%	-$8.98K	0.06%	99
2021 Q3	$260K	Sell	2,298 -65	-3%	-$7.42K	0.05%	103
2021 Q2	$245K	Sell	2,363 -53	-2%	-$5K	0.05%	108
2021 Q1	$202K	Sell	2,416 -258	-10%	-$21.8K	0.05%	117
2020 Q4	$244K	Sell	2,674 -50	-2%	-$4.15K	0.06%	93
2020 Q3	$217K	Sell	2,724 -33	-1%	-$2.58K	0.07%	85
2020 Q2	$190K	Buy	2,757 +33	+1%	+$2.35K	0.06%	94
2020 Q1	$171K	Sell	2,724 -1,335	-33%	-$96.3K	0.07%	81
2019 Q4	$315K	Buy	+4,059	New	+$317K	0.16%	61

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Column Capital Advisors's EW Position: Q3 2023 in Review

Column Capital Advisors held its Edwards Lifesciences (EW) position steady in Q3 2023 at 1,422 shares worth $98.5K. The position accounts for 0.01% of the portfolio, ranked #220.

Column Capital Advisors first reported a position in EW in Q4 2019 and has held it in 16 quarters since. The position peaked at $315K in Q4 2019. 1,220 funds tracked by Wall St. Rank hold EW as of Q3 2023.

Column Capital Advisors held 1,422 shares of Edwards Lifesciences worth $98.5K as of Q3 2023.
Column Capital Advisors left its Edwards Lifesciences share count unchanged in Q3 2023.
Edwards Lifesciences made up 0.01% of Column Capital Advisors's portfolio in Q3 2023, its #220 holding.
Column Capital Advisors first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 16 quarters since.
Column Capital Advisors's Edwards Lifesciences position peaked at $315K in Q4 2019.
1,220 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.